Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nagoya University Pancreatic Tumor Board Trial 08 (NUPAT-08)
jRCTs041200054Recruiting
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of paclitaxel and gemcitabine in pancreatic cancer (PC) (2 arms). Primary endpoint: 2-year survival rate. Started Jan 2021; status: recruiting.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs041200054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200054.